Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac–kidney–metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project

European Heart Journal Open · Published 2026-05-01 · DOI 10.1093/ehjopen/oeag077

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/ehjopen/oeag077

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles